Projection of top 10 orphan drugs by global revenue 2024

The data shows a projection of the top 10 global orphan drugs based on revenues in 2024. For that year, it is projected that Roche's and AbbVie's Venclexta will generate some 2.8 billion USD in revenue. Orphan drugs are used to target rare diseases or disorders, which in the U.S. is defined as less than 200,000 patients. The development of orphan drugs are currently incentivized in the U.S. through the Orphan Drug Act of 1983.